[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5723 Referred in Senate (RFS)]

<DOC>
115th CONGRESS
  2d Session
                                H. R. 5723


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             June 20, 2018

      Received; read twice and referred to the Committee on Finance

_______________________________________________________________________

                                 AN ACT


 
To require the Medicare Payment Advisory Commission to report on opioid 
   payment, adverse incentives, and data under the Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Expanding Oversight of Opioid 
Prescribing and Payment Act of 2018''.

SEC. 2. MEDICARE PAYMENT ADVISORY COMMISSION REPORT ON OPIOID PAYMENT, 
              ADVERSE INCENTIVES, AND DATA UNDER THE MEDICARE PROGRAM.

    Not later than March 15, 2019, the Medicare Payment Advisory 
Commission shall submit to Congress a report on, with respect to the 
Medicare program under title XVIII of the Social Security Act, the 
following:
            (1) A description of how the Medicare program pays for pain 
        management treatments (both opioid and non-opioid pain 
        management alternatives) in both inpatient and outpatient 
        hospital settings.
            (2) The identification of incentives under the hospital 
        inpatient prospective payment system under section 1886 of the 
        Social Security Act (42 U.S.C. 1395ww) and incentives under the 
        hospital outpatient prospective payment system under section 
        1833(t) of such Act (42 U.S.C. 1395l(t)) for prescribing 
        opioids and incentives under each such system for prescribing 
        non-opioid treatments, and recommendations as the Commission 
        deems appropriate for addressing any of such incentives that 
        are adverse incentives.
            (3) A description of how opioid use is tracked and 
        monitored through Medicare claims data and other mechanisms and 
        the identification of any areas in which further data and 
        methods are needed for improving data and understanding of 
        opioid use.

SEC. 3. NO ADDITIONAL FUNDS AUTHORIZED.

    No additional funds are authorized to be appropriated to carry out 
the requirements of this Act. Such requirements shall be carried out 
using amounts otherwise authorized to be appropriated.

            Passed the House of Representatives June 19, 2018.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.